Development and validation of UPLC-MS/MS method for in vitro quantitative analysis of pyrazinamide in lipid core-shell nanoarchitectonics for improved metabolic stability

Abstract Pyrazinamide (PZA), a medication for tuberculosis, has high aqueous solubility and low permeability, undergoes extensive liver metabolism, exhibits toxicity through its metabolites. To avoid this, PZA in lipid core-shell nanoarchitectonics been formulated to target lymphatic uptake provide metabolic stability the incorporated drug. The UPLC-MS/MS method reliable vitro quantitative analysis of pyrazinamide (PZA) as per ICH guidance was developed validated using HILIC column. is simple, precise, accurate, reproducible, sensitive estimation PZA-loaded determination % entrapment efficiency, loading pyrazinamide, microsomal human microsomes. efficiency found be 42.72% (±12.60). Lipid stable microsomes, where %QH 6.20%, that is, clearance. Thus, this formulation suitable preventing PZA-mediated metabolism. These findings are relevant development other lipid-mediated, suitable, nanoformulations containing various methods.